We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 65.27 | 65.44 | 66.03 | 91 | 10:52:24 |
From Apr 2019 to Apr 2024
By Jessica Sier
Gilead Sciences Inc.'s remdesivir has been granted marketing authorization by the European Commission for the treatment of coronavirus, the company said Friday.
The authorization allows the antiviral drug to be used in the European bloc in the treatment of patients with Covid-19 aged 12 and older who have pneumonia and require supplemental oxygen.
"The conditional marketing authorization was granted in the interest of public health due to the Covid-19 pandemic and was based on a rolling review of supporting data that began in April 2020," Gilead said.
The conditional marketing authorization is initially valid for one year, but can be extended.
In the U.S., remdesivir is authorized for use in emergencies for patients with severe coronavirus.
Write to Jessica Sier at jessica.sier@wsj.com
(END) Dow Jones Newswires
July 03, 2020 08:59 ET (12:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
